These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32199028)

  • 1. Neuroprotection induced by dexpramipexole delays disease progression in a mouse model of progressive multiple sclerosis.
    Buonvicino D; Ranieri G; Pratesi S; Gerace E; Muzzi M; Guasti D; Tofani L; Chiarugi A
    Br J Pharmacol; 2020 Jul; 177(14):3342-3356. PubMed ID: 32199028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mitochondriogenic but not the immunosuppressant effects of mTOR inhibitors prompt neuroprotection and delay disease evolution in a mouse model of progressive multiple sclerosis.
    Buonvicino D; Pratesi S; Ranieri G; Pistolesi A; Guasti D; Chiarugi A
    Neurobiol Dis; 2024 Feb; 191():106387. PubMed ID: 38142841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexpramipexole improves bioenergetics and outcome in experimental stroke.
    Muzzi M; Gerace E; Buonvicino D; Coppi E; Resta F; Formentini L; Zecchi R; Tigli L; Guasti D; Ferri M; Camaioni E; Masi A; Pellegrini-Giampietro DE; Mannaioni G; Bani D; Pugliese AM; Chiarugi A
    Br J Pharmacol; 2018 Jan; 175(2):272-283. PubMed ID: 28320070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroimmunological characterization of a mouse model of primary progressive experimental autoimmune encephalomyelitis and effects of immunosuppressive or neuroprotective strategies on disease evolution.
    Buonvicino D; Ranieri G; Pratesi S; Guasti D; Chiarugi A
    Exp Neurol; 2019 Dec; 322():113065. PubMed ID: 31536728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The small fiber neuropathy NaV1.7 I228M mutation: impaired neurite integrity via bioenergetic and mitotoxic mechanisms, and protection by dexpramipexole.
    Lee SI; Hoeijmakers JGJ; Faber CG; Merkies ISJ; Lauria G; Waxman SG
    J Neurophysiol; 2020 Feb; 123(2):645-657. PubMed ID: 31851560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexpramipexole blocks Nav1.8 sodium channels and provides analgesia in multiple nociceptive and neuropathic pain models.
    Urru M; Muzzi M; Coppi E; Ranieri G; Buonvicino D; Camaioni E; Coppini R; Pugliese AM; Tanaka B; Estacion M; Waxman SG; Dib-Hajj SD; Chiarugi A
    Pain; 2020 Apr; 161(4):831-841. PubMed ID: 31815915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexpramipexole enhances hippocampal synaptic plasticity and memory in the rat.
    Coppi E; Lana D; Cherchi F; Fusco I; Buonvicino D; Urru M; Ranieri G; Muzzi M; Iovino L; Giovannini MG; Pugliese AM; Chiarugi A
    Neuropharmacology; 2018 Dec; 143():306-316. PubMed ID: 30291939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.
    Cheah BC; Kiernan MC
    IDrugs; 2010 Dec; 13(12):911-20. PubMed ID: 21154151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with Non-specific HDAC Inhibitors Administered after Disease Onset does not Delay Evolution in a Mouse Model of Progressive Multiple Sclerosis.
    Buonvicino D; Ranieri G; Chiarugi A
    Neuroscience; 2021 Jun; 465():38-45. PubMed ID: 33862148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects.
    Bozik ME; Mather JL; Kramer WG; Gribkoff VK; Ingersoll EW
    J Clin Pharmacol; 2011 Aug; 51(8):1177-85. PubMed ID: 20959524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effects of exercise in people with progressive multiple sclerosis (Exercise PRO-MS): study protocol of a phase II trial.
    Gravesteijn AS; Beckerman H; de Jong BA; Hulst HE; de Groot V
    BMC Neurol; 2020 May; 20(1):177. PubMed ID: 32393193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
    de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J
    Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease modifying mitochondrial uncouplers, MP101, and a slow release ProDrug, MP201, in models of Multiple Sclerosis.
    Bando Y; Geisler JG
    Neurochem Int; 2019 Dec; 131():104561. PubMed ID: 31585135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing of dexpramipexole to treatment of neonatal hypoxic/ischemic encephalopathy.
    Muzzi M; Buonvicino D; Urru M; Tofani L; Chiarugi A
    Neurosci Lett; 2018 Nov; 687():234-240. PubMed ID: 30287306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size.
    Laidlaw TM; Prussin C; Panettieri RA; Lee S; Ferguson BJ; Adappa ND; Lane AP; Palumbo ML; Sullivan M; Archibald D; Dworetzky SI; Hebrank GT; Bozik ME
    Laryngoscope; 2019 Feb; 129(2):E61-E66. PubMed ID: 30284267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes.
    Panch SR; Bozik ME; Brown T; Makiya M; Prussin C; Archibald DG; Hebrank GT; Sullivan M; Sun X; Wetzler L; Ware J; Fay MP; Dunbar CE; Dworetzky SI; Khoury P; Maric I; Klion AD
    Blood; 2018 Aug; 132(5):501-509. PubMed ID: 29739754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
    Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
    Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chiral liquid chromatography-tandem mass spectrometry assay to determine that dexpramipexole is not converted to pramipexole in vivo after administered in humans.
    Wei D; Wu C; He P; Kerr D; Stecher S; Yang L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Nov; 971():133-40. PubMed ID: 25289790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating inflammation and neuroprotection in multiple sclerosis.
    Yong H; Chartier G; Quandt J
    J Neurosci Res; 2018 Jun; 96(6):927-950. PubMed ID: 28580582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.